Melody Parker
@melodyjp101.bsky.social
Bioinformatician/DPhil student at the University of Oxford.
Optimising direct-from-clinical-sample nanopore sequencing for pathogen identification and antimicrobial resistance prediction.
- Bacterial AMR outbreaks, MGEs
- Respiratory virus diagnostics
Optimising direct-from-clinical-sample nanopore sequencing for pathogen identification and antimicrobial resistance prediction.
- Bacterial AMR outbreaks, MGEs
- Respiratory virus diagnostics
🔹 Favourable outcomes in MYCN-amplified tumours require very high biosynthesis and ATM signalling — rarely achievable biologically.
Read here: biorxiv.org/content/10.1...
#neuroblastoma #modelling #cancerresearch
Read here: biorxiv.org/content/10.1...
#neuroblastoma #modelling #cancerresearch
A Novel Prognostic Metric Resolves the MYCN enigma in Silico and Points to a Biosynthetic Regulatory Shift Driven by MYCN Amplification in Neuroblastoma
Neuroblastoma (NB) is the most common extra-cranial solid tumour in children. Although MYCN amplification is typically indicative of a poor prognosis, the expression level of MYCN has a non-monotonic ...
biorxiv.org
November 15, 2025 at 2:26 PM
🔹 Favourable outcomes in MYCN-amplified tumours require very high biosynthesis and ATM signalling — rarely achievable biologically.
Read here: biorxiv.org/content/10.1...
#neuroblastoma #modelling #cancerresearch
Read here: biorxiv.org/content/10.1...
#neuroblastoma #modelling #cancerresearch
We propose:
🔹 The p53/MYCN ratio is a superior prognostic metric to MYCN alone in neuroblastoma.
🔹 MYCN drives biogenesis, but amplification or co-mutations trigger a shift that lowers p53/MYCN → worse outcomes.
⬇️
🔹 The p53/MYCN ratio is a superior prognostic metric to MYCN alone in neuroblastoma.
🔹 MYCN drives biogenesis, but amplification or co-mutations trigger a shift that lowers p53/MYCN → worse outcomes.
⬇️
November 15, 2025 at 2:25 PM
We propose:
🔹 The p53/MYCN ratio is a superior prognostic metric to MYCN alone in neuroblastoma.
🔹 MYCN drives biogenesis, but amplification or co-mutations trigger a shift that lowers p53/MYCN → worse outcomes.
⬇️
🔹 The p53/MYCN ratio is a superior prognostic metric to MYCN alone in neuroblastoma.
🔹 MYCN drives biogenesis, but amplification or co-mutations trigger a shift that lowers p53/MYCN → worse outcomes.
⬇️